CellWell record HH-377595
NST-1024 for the treatment of very high triglycerides: A placebo-controlled, randomized, double-blind, 28-day clinical trial
Kastelein JJ; Skjæret T; Jeannin S; Beyusen R; Fraser DA; Maki KC
Journal of clinical lipidology · 2026
In plain language
In a 4-week placebo-controlled trial of 44 adults with severe hypertriglyceridemia, the EPA derivative NST-1024 lowered triglycerides by a placebo-corrected 31.8% and also reduced fasting glucose and C-peptide.
- Evidence
- Emerging
- Design
- Primary research (design unspecified)
Cite this record: https://thecellwell.org/studies/HH-377595
Produced by the CellWell Research Engine, custom software owned and operated by CellWell and The Holistic Hub. All rights reserved. This analysis, its indexing and its evidence classifications are proprietary. Any use, republication or onward sharing must credit CellWell Research Engine (thecellwell.org) as the source.
This is an educational research library, not medical advice. Nothing here may be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified professional.